Leukemia, Myeloid, Chronic-Phase
"Leukemia, Myeloid, Chronic-Phase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
| Descriptor ID |
D015466
|
| MeSH Number(s) |
C04.557.337.539.250.400 C15.378.190.636.370.400
|
| Concept/Terms |
Leukemia, Myeloid, Chronic-Phase- Leukemia, Myeloid, Chronic-Phase
- Granulocytic Leukemia, Chronic, Stable-Phase
- Leukemia, Granulocytic, Chronic Phase
- Leukemia, Granulocytic, Chronic-Phase
- Leukemia, Myelogenous, Chronic Phase
- Leukemia, Myelogenous, Chronic-Phase
- Leukemia, Myeloid, Chronic Phase
- Leukemia, Myeloid, Stable Phase
- Leukemia, Myeloid, Stable-Phase
- Myelogenous Leukemia, Chronic, Chronic Phase
- Myelogenous Leukemia, Chronic, Chronic-Phase
- Myeloid Leukemia, Chronic, Chronic Phase
- Myeloid Leukemia, Chronic, Chronic-Phase
- Myeloid Leukemia, Chronic, Stable-Phase
- Granulocytic Leukemia, Chronic, Stable Phase
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Chronic-Phase".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Leukemia, Myeloid, Chronic-Phase [C04.557.337.539.250.400]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Leukemia, Myeloid, Chronic-Phase [C15.378.190.636.370.400]
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Chronic-Phase".
This graph shows the total number of publications written about "Leukemia, Myeloid, Chronic-Phase" by people in this website by year, and whether "Leukemia, Myeloid, Chronic-Phase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myeloid, Chronic-Phase" by people in Profiles.
-
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2024 Mar 01; 42(7):821-831.
-
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol. 2018 Aug; 97(8):1357-1367.
-
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74.
-
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):341-349.e1.
-
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407.
-
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12.
-
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74.
-
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014 Sep; 28(5):179-87.
-
Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8.
-
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9.